These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3579676)

  • 1. Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis. Results of a multicenter, double-blind study.
    Jacobs L; Salazar AM; Herndon R; Reese PA; Freeman A; Jozefowicz R; Cuetter A; Husain F; Smith WA; Ekes R
    Arch Neurol; 1987 Jun; 44(6):589-95. PubMed ID: 3579676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis.
    Jacobs L; Salazar AM; Herndon R; Reese PA; Freeman A; Josefowicz R; Cuetter A; Husain F; Smith WA; Ekes R
    Lancet; 1986 Dec 20-27; 2(8521-22):1411-3. PubMed ID: 2878272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis.
    Camenga DL; Johnson KP; Alter M; Engelhardt CD; Fishman PS; Greenstein JI; Haley AS; Hirsch RL; Kleiner JE; Kofie VY
    Arch Neurol; 1986 Dec; 43(12):1239-46. PubMed ID: 3535752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic alpha-interferon therapy of multiple sclerosis.
    Knobler RL; Panitch HS; Braheny SL; Sipe JC; Rice GP; Huddlestone JR; Francis GS; Hooper CK; Kamin-Lewis RM; Johnson KP
    Neurology; 1984 Oct; 34(10):1273-9. PubMed ID: 6384817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrathecal interferon in the treatment of multiple sclerosis. Patient follow-up.
    Jacobs L; O'Malley JA; Freeman A; Ekes R; Reese PA
    Arch Neurol; 1985 Sep; 42(9):841-7. PubMed ID: 4026626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrathecal interferon in multiple sclerosis.
    Jacobs L; O'Malley J; Freeman A; Murawski J; Ekes R
    Arch Neurol; 1982 Oct; 39(10):609-15. PubMed ID: 6751302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
    Neurology; 1993 Apr; 43(4):655-61. PubMed ID: 8469318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic interferon therapy of multiple sclerosis: the pros.
    Knobler RL
    Neurology; 1988 Jul; 38(7 Suppl 2):58-61. PubMed ID: 3133575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
    Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH
    Mult Scler; 1995 Jun; 1(2):118-35. PubMed ID: 9345462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous natural beta interferon treatment of chronic exacerbating-remitting multiple sclerosis: clinical response and MRI/CSF findings.
    Huber M; Bamborschke S; Assheuer J; Heiss WD
    J Neurol; 1988 Jan; 235(3):171-3. PubMed ID: 3367166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxic effects of interferon administered intrathecally.
    Ruutiainen J; Panelius M; Cantell K
    Br Med J (Clin Res Ed); 1983 Mar; 286(6369):940. PubMed ID: 6403145
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results.
    Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group
    Neurology; 2001 Jun; 56(11):1496-504. PubMed ID: 11402106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial of natural alpha interferon in multiple sclerosis.
    Knobler RL; Panitch HS; Braheny SL; Sipe JC; Rice GP; Huddlestone JR; Francis GS; Hooper CJ; Kamin-Lewis RM; Johnson KP
    Ann N Y Acad Sci; 1984; 436():382-8. PubMed ID: 6398020
    [No Abstract]   [Full Text] [Related]  

  • 17. Systemic alpha-interferon in multiple sclerosis. Long-term patient follow-up.
    Panitch HS
    Arch Neurol; 1987 Jan; 44(1):61-3. PubMed ID: 3800723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-alpha and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. AUSTIMS Research Group.
    J Neurol Neurosurg Psychiatry; 1989 May; 52(5):566-74. PubMed ID: 2659737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The placebo effect during a double blind trial of recombinant alpha 2 interferon in multiple sclerosis patients: immunological and clinical findings.
    Hirsch RL; Johnson KP; Camenga DL
    Int J Neurosci; 1988 Apr; 39(3-4):189-96. PubMed ID: 3045033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
    Lancet; 1998 Nov; 352(9139):1491-7. PubMed ID: 9820296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.